Therapeutic Asset Ratings

361 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
COLCHICINUM Obesity	Donders Centre for Cognitive Neuroimaging	P2	B (56)
Danuglipron Obesity	Pfizer	P2	B (56)
EUDEMINE INJECTION Obesity	Columbia University	P2	B (56)
Intralipid Obesity	Yale University	P2/3	B (56)
Insulin Detemir Obesity	Vanderbilt University	P4	CCC (55)
INSULIN GLARGINE (SANOFI) Obesity	Eli Lilly and Company	P4	CCC (55)
Methylphenidate Obesity	University Hospital, Tours	P4	CCC (55)
PHYSIOLOGIC SODIUM CHLORIDE SOLUTION Obesity	Cambridge University Hospitals NHS Foundation Trust	P4	CCC (55)
SUFENTANYL Obesity	IVO JURISIC	P4	CCC (55)
ADVICOR COMPONENT NIACIN Obesity	Université de Sherbrooke	P2	CCC (55)
FLAVONE, 3,3',4',5,7-PENTAHYDROXY- Obesity	Cedars-Sinai Medical Center	P2/3	CCC (55)
Biktarvy Obesity	East Carolina University	P4	CCC (54)
Clinisol 15% Obesity	Mayo Clinic	P4	CCC (54)
DEXTROSE Obesity	Mayo Clinic	P4	CCC (54)
Erythromycin Obesity	Universitaire Ziekenhuizen KU Leuven	P4	CCC (54)
Esomeprazole Obesity	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	P4	CCC (54)
IMIPENEM Obesity	University of Illinois at Chicago	P4	CCC (54)
lcz696 Obesity	Ohio State University	P4	CCC (54)
Metyrapone Obesity	Eleonora Seelig	P4	CCC (54)
PANITUMUMAB Obesity	Laval University	P4	CCC (54)
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]- Obesity	Hospital General Tlahuac	P4	CCC (54)
Rfsh Obesity	Fundacion Dexeus	P4	CCC (54)
Saroglitazar Obesity	Zydus Lifesciences Limited	P4	CCC (54)
Symtuza Obesity	East Carolina University	P4	CCC (54)
Aleniglipron Obesity	Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics	P3	CCC (54)

Showing 101 to 125 of 361 assets

PreviousPage 5 of 15Next